ReviewCurrent opinion in psychiatry2013
Polypharmacy for schizophrenia.
Review in Current opinion in psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comprehensive characterization of chronic midazolam exposure on neonates and long-term neurodevelopment.Molecular psychiatry · 2025Article
- Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis.Psychopharmacology · 2024Article
- Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort.Frontiers in pharmacology · 2024Article
- Exposure to psychotropic medications and mortality in schizophrenia: a 5-year national cohort study.Psychological medicine · 2023Article
- Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics-An Observational Study.Brain sciences · 2023Article
- The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders.Frontiers in psychiatry · 2023Article
- Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States.Psychiatric services (Washington, D.C.) · 2022Article
- The Mental Health of Patients With Psychotic Disorder From a Positive, Multidimensional and Recovery Perspective.Frontiers in psychology · 2022Article
- Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.Drugs · 2021Review
- Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia.Frontiers in psychiatry · 2021Article
- Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID).Journal of clinical pathology · 2020Article
- Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.JAMA psychiatry · 2019Article
- Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient Hospitals.Journal of psychiatric practice · 2016Article
- Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Article
- Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial.Iranian journal of psychiatry and behavioral sciences · 2015Article
- Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Current treatment options in psychiatry · 2015Article
- What does schizophrenia teach us about antipsychotics?Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Review
- A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidone.Innovations in clinical neuroscience · 2013Article
- Use of Benzodiazepines and Antipsychotic Drugs Are Inversely Associated With Acute Readmission Risk in Schizophrenia.Journal of clinical psychopharmacologyObservational
- Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewCombining psychotropic medications is common for people diagnosed with schizophrenia facing a variety of clinical circumstances. This review provides an update on evidence regarding the effectiveness of polypharmacy approaches. RECENT
findingsEpidemiology studies have demonstrated that polypharmacy is extremely common, but evidence regarding all polypharmacy approaches for schizophrenia from randomized controlled trials remains scarce. Combinations of antipsychotic medicines are unsupported by evidence. Antidepressants are commonly used to treat depressive symptoms; this logical role for antidepressants has little support from randomized controlled trials (RCTs) but may be associated with lower suicide and all-cause mortality. Insufficient evidence supports the use of benzodiazepines for schizophrenia; possible risks of benzodiazepines, including increased mortality rates revealed in observational studies, warrant caution and further study. SUMMARY: The lack of evidence regarding common treatment strategies exacerbates the tremendous challenge of providing optimal pharmacotherapy for individuals with schizophrenia. Comparative effectiveness research, using observational methods when appropriate and RCTs when possible, is needed to inform clinical practice, use resources wisely and improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.